2011, nr. 1 - Academia de Ştiinţe a Moldovei

Ştiinţe Medicale
and risk of stroke in patients with asymptomatic internal-carotid-artery
stenosis. North American Symptomatic Carotid
Endarterectomy Trial Collaborators. N. Engl. J. Med., 2000;
342:1693–1700.
10. Grosu A. Fibrilaţia atrială, Chișinău, 2006, p. 22,
64.
11. Watson T., Shantsila E., Lip G. Y. Mechanisms of
thrombogenesis in atrial fi brilla tion: Virchow’s triad revisited.
Lancet, 2009; 373:155–166.
12. Al-Saady N. M., Obel O. A., Camm A. J. Th e left
atrial appendage: structure, function and role in thromboembolism,
Heart., 1999; vol. 82:547-555.
13. Roldan V., Marin F., Marco P. et al. Hypofi brinolysis
in atrial fi brillation, Amer. Heart J. – 1998, vol.136:956-
960.
14. Goldsmith I., Blann A.D., Patel R.L. et.al. Reduced
indices of left atrial hypercoagulability in patients with severe
mitral regurgitation. Amer. J. Cardiology, 2000, vol. 86:234-
236.
15. Fuster V., Ryden L., Asinger R. et al. ACC/AHA/
ESC Guidelines for the management of patients with atrial
fi brillation: executive summary. Circulation, 2001, vol.
104:2118-2150.
16. Sacco R.L., Adams R., Albers G. et al. Guidelines
for prevention of stroke in patients with ischemic stroke or
transient ischemic attack. Stroke, 2006; 37:577-617.
17. Akdemir I., Dagdelen S., Yuce M. et al. Silent brain
infarction in patients with rheumatic mitral stenosis. Jpn.
Heart. J., 2002; 43:137-44.
18. Vahanian A., Baumgartner H., Bax J. et al. Guidelines
on the management of valvular heart disease: the Task
Force on the Management of Valvular Heart Disease of the
European Society of Cardiology. Eur. Heart. J. 2007; 28:230–
268.
19. Mylonakis E., Calderwood S.B. Infective endocarditis
in adults. N. Engl. J. Med., 2001, 345:1318-1330.
20. Matcher D.B. et al. Medical treatment for stroke prevention.
Annals of Int. Med., 1994; 121(1):54-55.
21. Predictors of major vascular events in patients with
transient ischaemic attack or minor stroke and non-rheumatic
atrial fi brillation. EAFT Study Group. Stroke, 1995,
vol.26:801-806.
22. Vermeer Se et al. Asymptomatic stroke. Lancet Neurol.,
2007; 6:611-9.
23. Dickstein K., Cohen-Solal A., Filippatos G. et al.
ESC Guidelines for the diagnosis and treatment of acute and
chronic heart failure 2008. Eur. Heart. J., 2008; 29:2388–
2442.
24. Stroke in AF working group. Independent predictors
of stroke in patients with atrial fi brillation: a systematic
review. Neurology., 2007; 69:546–554.
25. Autors/ Task Force Members: A. John Camn, Paulus
Kirchhof, Gregory Y. H. Lip Guidelines for the management
of atrial fi brillation. European Heart. J., 2010; 31:
2369-2429.
26. Шевченко О.П. Артериальная гипертония и
церебральный инсульт.М: Реафарм 2001; 191.
27. Taylor A.J., Kent S.M., Flaherty P.J. et al. ARBITER:
Arterial Biology for the Investigation of the Treatment Eff ects
51
of Reducing Cholesterol: a randomized trial comparing the
eff ects of atorvastatin and pravastatin on carotid intima medial
thickness. Circulation, 2002; 106:2055-60.
28. Д.В. Преображенский. Инсульт и другие
тромбоэмболические осложнения при мерцании
предсердий. Часть I. Распространенность и факторы
риска. Кардиология, 2004; 3:83-86.
29. People with diabetes are at higher risk of atrial fi -
brillation, Published: Th ursday, 2010; 18:12 in Health &
Medicine.
30. Gregory Y. H., Watson T., Shantsila E. Anticoagulation
for stroke prevention in atrial fi brillation: is gender
important? Euro Heart. J., 2006; 27:1893-1894.
31. Fang M.C., Singer DE., Chang Y. et al. Gender diff
erences in the risk of ischemic stroke and peripheral embolism
in atrial fi brillation,(ATRIA) study. Circulation, 2005;
112:687–1691.
32. Amarenco P., Tonkin A.M. Statins for stroke prevention:
disappointment and hope. Circulation., 2004;
109:III-44–III-49.
33. Marcucci R., Betti I., Cecchi E., et al. Hyperhomocy-steinemia
and vitamin B6 defi ciency: new risk markers
for nonvalvular atrial fi brillation? Am. Heart. J. 2004;
148:456-61.
34. Fontaine K.R., Redden D.T., Wang C. et al. Years of
life lost due to obesity. JAMA. 2003; 289:187–193.
35. Sascha Dublin et al. Infl uence of high body index
to risk of atrial fi brillation and stroke. Arch. Intern. Med.,
2007;166:2322-2328.
36. Towfi ghi Amytis et al. NHANES (National Health
and Nutrition Examination Survey) 1999-2004. Neurulogy,
2007; advance online publication.
37. Conway D.S.G., Buggin P., Hughes E. et al. Relation
of interleukin-6, C-reactive protein, and the prothrombotic
state to transesophageal echocardiographic fi ndings in
atrial fi brillation. Am. J. Cardiol., 2004; 93:1368-1373.
38. Д-р F. Purroy и коллеги (Университетская
Клиника Arnau de Villanova, Lleida, Испания).
С-реактивный белок предсказывает риск повторных
сосудистых событий. Acta Neurol. Scand., 2007; 15:60-
66.
39. Koen Putman. Образовательный уровень
инсультных больных определяет ответ на
реабилитацию в стационаре, уровень дохода -
восстановление после выписки. J. Neurol. Neurosurg.
Psychiatry, 2006; advance online publication 25.12.2006.
Rezumat
Lucrarea de faţă își propune să analizeze principalii
factori de risc de dezvoltare a accidentelor vasculare
cerebrale ischemice și impactul lor la bolnavii cu FA,
deoarece această patologie este extrem de răspândită
și are costuri economico-sociale ridicate. Ictusul este
o afecţiune heterogenă multifactorială, influenţată de
factori de risc modificabili și nemodificabili. Factorii
de risc modificabili includ anamneza de hipertensiune
arterială, diabet zaharat și cardiopatie ischemică. Factorii
de risc nemodificabili includ vârsta, genul și rasa.
Alţi factori de risc mai puţin documentaţi sunt locali-